Effectiveness of sparfloxacin for Chlamydia pneumoniae infection in patients with bronchial asthma

In order to evaluate the effectiveness of sparfloxacin (SPFX), a synthetic new quinolone antibacterial agent 26 patients with bronchial asthma, in whom Chlamydia (C.) pneumoniae IgG and IgA antibody titers (ID) were elevated more than 1.01 were studied. They were divided at random into two groups: SPFX administration group (14 patients) and non-administration group (12 patients). In SPFX administration group, 200mg/day of this drug was administered for 3 weeks. In the SPFX administration group, a significant improvement in serum CRP, and significant decreases in peripheral eosinophil count, serum ECP, and sputum ECP were observed. Furthermore, there were also noted significant decreases in frequency of asthmatic attacks in frecuency of inhalation of β₂ stimulant, and a significant increse in PEE in the morning. Thus, it was suggested that administration of SPFX was effective for patients with bronchial asthma accompanying persistent C. pneumoniae infection.